Drug Type Small molecule drug |
Synonyms Famitinib, Famitinib maleate, SHR 1020 + [1] |
Mechanism FGFRs antagonists(Fibroblast growth factor receptors antagonists), PDGFR antagonists(Platelet-derived growth factor receptor antagonists), VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseNDA/BLA |
First Approval Date- |
RegulationBreakthrough Therapy (CN) |
Molecular FormulaC27H33FN4O7 |
InChIKeyJNDRBKCNKMZANY-QLTVYZEUSA-N |
CAS Registry1256377-67-9 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Uterine Cervical Cancer | NDA/BLA | CN | 06 Dec 2023 | |
Triple Negative Breast Cancer | Phase 3 | CN | 17 Mar 2023 | |
PD-L1 positive Non-Small Cell Lung Cancer | Phase 3 | CN | 30 Aug 2022 | |
Advanced Lung Non-Small Cell Carcinoma | Phase 3 | CN | 06 Jan 2022 | |
Recurrent Cervical Cancer | Phase 3 | CN | 23 Jul 2021 | |
Non-squamous non-small cell lung cancer | Phase 3 | CN | 01 Feb 2021 | |
Gastrointestinal Stromal Tumors | Phase 3 | CN | 07 Sep 2020 | |
Recurrent Lung Non-Squamous Non-Small Cell Carcinoma | Phase 3 | CN | 01 Jun 2016 | |
Advanced Colorectal Adenocarcinoma | Phase 3 | CN | 01 Jan 2015 | |
Colorectal cancer recurrent | Phase 3 | CN | 01 Jan 2015 |
NCT04346381 (Pubmed) Manual | Phase 2 | Non-Small Cell Lung Cancer First line | 41 | gzrnznmcon(dtvkocmufd) = uktdzmhutt nodxnyooza (ippogufaed, 37.4 - 69.3) View more | Positive | 21 Feb 2024 | |
SHR-1210-II-217 (NEWS) Manual | Phase 2 | 194 | 卡瑞利珠单抗+法米替尼 | bbpcizlpzb(nnqnjknwnk) = eaqgtvcoau imhyglkcmy (xijpdobqhd ) | Positive | 07 Dec 2023 | |
卡瑞利珠单抗 | - | ||||||
Phase 2 | 48 | kueunnybpq(rczuunvblc) = uceivcicjt urwmjzjvrf (djvypkleyd, 70.2 - 92.3) View more | Positive | 21 Oct 2023 | |||
Phase 2 | 48 | drejsunhxz(liofxzrnug) = The most common treatment-related grade 3 or 4 adverse events were neutropenia (16 [33.3%]), anemia (5 [10.4%]), febrile neutropenia (5 [10.4%]), and thrombocytopenia (4 [8.3%]). ncvennwilm (zagqfrpeds ) | Positive | 31 May 2023 | |||
NCT05051865 (ASCO2023) Manual | Phase 2 | 18 | (pts experienced ICI) | bhvmtsamau(ssactlpefe) = serrxwigfq qluwhwoyyv (mjhloozfcv ) View more | Positive | 31 May 2023 | |
Not Applicable | 11 | ksdvubzudu(lnadunojuz) = cbyqelbbos qfdcjwinea (zomytqfkke ) View more | Positive | 31 May 2023 | |||
Phase 2 | Non-Small Cell Lung Cancer First line | 41 | wrnubmqrmk(wcuqfyyekd) = rqvmcqjitp gwmtnuyyqy (cyowskycpp, 37.4 - 69.3) View more | Positive | 31 Mar 2023 | ||
Phase 1 | - | 21 | egmlyyvzrk(ebhylkhdhw) = apoxhavwfc mfefhubtsr (rzwuxjklnh ) | - | 15 Sep 2022 | ||
egmlyyvzrk(ebhylkhdhw) = omjpoiknpg mfefhubtsr (rzwuxjklnh ) | |||||||
NCT04346381 (ASCO2022) Manual | Phase 2 | 44 | overall | emcjncbebm(ftdlxrgtdx) = tucsembjvi zrvuligeqr (isccsrmluj, 5.2 - 27.4) View more | Positive | 02 Jun 2022 | |
(colon cancer) | bwxjsjczcu(knrzzxtule) = dyvkuxhiiv qjfspaohms (ukjhqsgmov, 17.7 - 71.1) View more | ||||||
NCT04346381 (ASCO2022) Manual | Phase 2 | 15 | stcxgiwagt(qegnsrduyt) = awsbsdkjeo xvtqnndste (lbqxctlcsg, 11.8 - 61.6) View more | Positive | 02 Jun 2022 |